{"id":"https://openalex.org/W4379284129","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.tps634","title":"Neoadjuvant HER2-targeted therapy \u00b1 immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.","display_name":"Neoadjuvant HER2-targeted therapy \u00b1 immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.","publication_year":2023,"publication_date":"2023-06-01","ids":{"openalex":"https://openalex.org/W4379284129","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.tps634"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2023.41.16_suppl.tps634","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.tps634","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.2023.41.16_suppl.tps634","pdf_url":"https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.16_suppl.TPS634?role=tab","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.16_suppl.TPS634?role=tab","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5007002927","display_name":"Heather L. McArthur","orcid":"https://orcid.org/0000-0002-0201-3871","observed_orcids":["https://orcid.org/0000-0002-0201-3871"]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heather L. McArthur","raw_affiliation_strings":["University of Texas Southwestern Medical Center, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas Southwestern Medical Center, Dallas, TX","institution_ids":["https://openalex.org/I867280407"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042082543","display_name":"Jorge Henrique Santos Leal","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jorge Leal","raw_affiliation_strings":["Clion - CAM Group, Salvador, Bahia, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clion - CAM Group, Salvador, Bahia, Brazil","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063600668","display_name":"Stephen Lawrence Shiao","orcid":"https://orcid.org/0000-0001-7586-2885","observed_orcids":["https://orcid.org/0000-0001-7586-2885"]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen Lawrence Shiao","raw_affiliation_strings":["Cedars-Sinai Medical Center, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars-Sinai Medical Center, Los Angeles, CA","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006071406","display_name":"Meredith Carter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Meredith Carter","raw_affiliation_strings":["University of Texas Southwestern Medical Center, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas Southwestern Medical Center, Dallas, TX","institution_ids":["https://openalex.org/I867280407"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039500399","display_name":"Reva Kakkar Basho","orcid":"https://orcid.org/0000-0002-4132-7523","observed_orcids":["https://orcid.org/0000-0002-4132-7523"]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Reva K Basho","raw_affiliation_strings":["Cedars-Sinai Medical Center, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars-Sinai Medical Center, Los Angeles, CA","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033380289","display_name":"Michelle Phillips","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michelle Phillips","raw_affiliation_strings":["Cedars-Sinai Medical Center, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars-Sinai Medical Center, Los Angeles, CA","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075070960","display_name":"David W. Chan","orcid":"https://orcid.org/0000-0002-6951-3467","observed_orcids":["https://orcid.org/0000-0002-6951-3467"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Chan","raw_affiliation_strings":["Cancer Care Assoc-TMPN, Redondo Beach, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Care Assoc-TMPN, Redondo Beach, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061205710","display_name":"Hugo Hool","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hugo Hool","raw_affiliation_strings":["Cancer Care Associates, Torrance, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Care Associates, Torrance, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050447425","display_name":"Dorothy J. Park","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dorothy J. Park","raw_affiliation_strings":["Cedars-Sinai Cancer, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars-Sinai Cancer, Los Angeles, CA","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062700636","display_name":"Mary El-Masry","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary El-Masry","raw_affiliation_strings":["Cedars Sinai Tower Hematology Oncology, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars Sinai Tower Hematology Oncology, Los Angeles, CA","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109576591","display_name":"Philomena F. McAndrew","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philomena McAndrew","raw_affiliation_strings":["Cedars-Sinai Cancer, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars-Sinai Cancer, Los Angeles, CA","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052786666","display_name":"Swati Sikaria","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Swati Sikaria","raw_affiliation_strings":["Cancer Care Associates, Torrance, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Care Associates, Torrance, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018738915","display_name":"Laura M. Spring","orcid":"https://orcid.org/0000-0001-8904-3514","observed_orcids":["https://orcid.org/0000-0001-8904-3514"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura Spring","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034972183","display_name":"Aditya Bardia","orcid":"https://orcid.org/0000-0003-4885-1157","observed_orcids":["https://orcid.org/0000-0003-4885-1157"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aditya Bardia","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030308961","display_name":"Mourad Tighiouart","orcid":"https://orcid.org/0000-0001-8021-5690","observed_orcids":["https://orcid.org/0000-0001-8021-5690"]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mourad Tighiouart","raw_affiliation_strings":["Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035442509","display_name":"Farnaz Dadmanesh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Farnaz Dadmanesh","raw_affiliation_strings":["Cedars-Sinai Medical Center, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars-Sinai Medical Center, Los Angeles, CA","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109315401","display_name":"Armando E. Giuliano","orcid":"https://orcid.org/0000-0002-5421-945X","observed_orcids":["https://orcid.org/0000-0002-5421-945X"]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Armando E. Giuliano","raw_affiliation_strings":["Cedars-Sinai Medical Center, Beverly Hills, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars-Sinai Medical Center, Beverly Hills, CA","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112703495","display_name":"Katherine G. Sanchez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210141130","display_name":"New Mexico Cancer Center","ror":"https://ror.org/03emyr182","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210141130"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katherine Sanchez","raw_affiliation_strings":["New Mexico Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New Mexico Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I4210141130"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5017531113","display_name":"David B. Page","orcid":"https://orcid.org/0000-0001-9264-4628","observed_orcids":["https://orcid.org/0000-0001-9264-4628"]},"institutions":[{"id":"https://openalex.org/I2801670537","display_name":"Providence Portland Medical Center","ror":"https://ror.org/015tmw922","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801670537","https://openalex.org/I4210160466","https://openalex.org/I94396219"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David B. Page","raw_affiliation_strings":["Providence Cancer Institute, Portland, OR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Providence Cancer Institute, Portland, OR","institution_ids":["https://openalex.org/I2801670537"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"41","issue":"16_suppl","first_page":"TPS634","last_page":"TPS634"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9092000126838684,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9092000126838684,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.03220000118017197,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.030300000682473183,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.8880000114440918},{"id":"https://openalex.org/keywords/neoadjuvant-therapy","display_name":"neoadjuvant therapy","score":0.9789999723434448},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9670000076293945},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7229999899864197},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9929999709129333},{"id":"https://openalex.org/keywords/pertuzumab","display_name":"pertuzumab","score":0.9879999756813049},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.984000027179718},{"id":"https://openalex.org/keywords/pathological-complete-response","display_name":"pathological complete response","score":0.8159999847412109},{"id":"https://openalex.org/keywords/her2-targeted-therapy","display_name":"HER2-targeted therapy","score":0.6200000047683716},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.7269999980926514},{"id":"https://openalex.org/keywords/axillary-lymph-node-response","display_name":"axillary lymph node response","score":0.5350000262260437},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.44699999690055847}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9441166520118713},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.7060045599937439},{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.6835696697235107},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6711780428886414},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.661304771900177},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5571333765983582},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.535496711730957},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.48161715269088745},{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.4706494212150574},{"id":"https://openalex.org/C2778292576","wikidata":"https://www.wikidata.org/wiki/Q6991934","display_name":"Neoadjuvant therapy","level":4,"score":0.42112353444099426},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.4200844466686249},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4101516604423523},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.39681321382522583},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3898550271987915},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.32956069707870483}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2023.41.16_suppl.tps634","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.tps634","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.2023.41.16_suppl.tps634","pdf_url":"https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.16_suppl.TPS634?role=tab","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1200/jco.2023.41.16_suppl.tps634","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.tps634","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.2023.41.16_suppl.tps634","pdf_url":"https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.16_suppl.TPS634?role=tab","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320306260","display_name":"Breast Cancer Research Foundation","ror":"https://ror.org/0348ff195"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4379284129.pdf","grobid_xml":"https://content.openalex.org/works/W4379284129.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2978186977","https://openalex.org/W4396587112","https://openalex.org/W4249577962","https://openalex.org/W4322771612","https://openalex.org/W4411289485","https://openalex.org/W2944776474","https://openalex.org/W3013417770","https://openalex.org/W1982825879","https://openalex.org/W3208653333","https://openalex.org/W2754374743"],"abstract_inverted_index":{"TPS634":[0],"Background:":[1],"Immune":[2],"checkpoint":[3],"inhibition":[4],"(ICI)":[5],"is":[6,263,288],"synergistic":[7],"with":[8,21,83,93,123,244],"HER2-directed":[9,19],"therapy":[10,20],"in":[11,30,47,56,294],"pre-clinical":[12],"models.":[13],"Clinically,":[14],"pembrolizumab":[15],"(K)-mediated":[16],"ICI":[17,38],"plus":[18,95,198],"trastuzumab":[22],"(H)":[23],"was":[24,228,235],"safe":[25],"and":[26,53,71,81,108,134,143,167,182,230,251,297,309,323],"demonstrated":[27],"modest":[28],"activity":[29,43],"H-resistant":[31],"HER2-positive":[32],"(HER2+)":[33],"metastatic":[34],"breast":[35,129,296,318],"cancer.":[36],"Because":[37],"may":[39,61,86],"confer":[40,67],"more":[41],"robust":[42],"when":[44],"administered":[45,55],"earlier":[46],"the":[48,57,77,88,106,240,267,276,295],"course":[49],"of":[50,65,79,110,217,259,335],"disease,":[51],"H":[52,80,94,162],"K":[54,82,199],"curative-intent,":[58],"treatment-naive":[59],"setting":[60],"allow":[62],"for":[63,90,159],"de-escalation":[64],"cytotoxics;":[66],"life-long,":[68],"tumor-specific":[69],"immunity;":[70],"ultimately,":[72],"improve":[73],"cure":[74],"rates.":[75],"Moreover,":[76],"synergy":[78],"paclitaxel":[84],"(T)":[85],"overcome":[87],"need":[89],"dual":[91],"HER2-blockade":[92],"pertuzumab":[96],"(P).":[97],"In":[98,150,192,209],"this":[99,233],"randomized,":[100],"multicenter,":[101],"phase":[102],"II,":[103],"open-label":[104],"trial":[105,340],"efficacy":[107,226,336],"safety":[109,322],"neoadjuvant":[111],"THP":[112,197],"vs":[113,115],"THP-K":[114],"TH-K":[116],"are":[117,131,273],"explored.":[118],"Methods:":[119],"Patients":[120],"(pts)":[121],"\u226518y":[122],"previously":[124],"untreated,":[125],"stage":[126],"II-III,":[127],"HER2+":[128],"cancer":[130,312],"being":[132],"randomized":[133],"stratified":[135],"by":[136,307],"clinical":[137,282],"nodal":[138],"status":[139,146],"(positive":[140,147],"vs.":[141,148],"negative)":[142],"hormone":[144],"receptor":[145],"negative).":[149],"arm":[151,193,210,221,234,249,256],"A,":[152],"pts":[153,195,212,219,246,253,272],"received":[154,196,213],"T":[155],"at":[156,163,177,200],"80mg/m2":[157],"weekly":[158],"12":[160],"weeks,":[161],"8mg/Kg":[164],"(loading":[165,180],"dose)":[166,181],"then":[168,183],"6mg/Kg":[169],"every":[170,185,202],"3":[171,174,186,189,203],"weeks":[172,187,204,265],"x":[173,188,205],"doses,":[175],"P":[176],"840":[178],"mg":[179],"420mg/Kg":[184],"doses":[190,207],"(THP).":[191],"B,":[194],"200mg":[201],"4":[206],"(THP-K).":[208],"C,":[211,222],"TH-K.":[214],"After":[215,270],"enrollment":[216,231],"22":[218],"to":[220,232,239,248,255],"a":[223],"prespecified":[224],"interim":[225],"analysis":[227],"conducted,":[229],"subsequently":[236],"terminated.":[237],"Enrollment":[238],"other":[241],"arms":[242],"continues":[243],"32/58":[245],"enrolled":[247,254],"A":[250],"33/58":[252],"B":[257],"as":[258],"2/14/2023.":[260],"Definitive":[261],"surgery":[262,320],"3-6":[264],"after":[266],"last":[268],"dose.":[269],"surgery,":[271],"treated":[274],"per":[275,280],"treating":[277],"physician\u2019s":[278],"discretion":[279],"local":[281],"standard.":[283],"The":[284],"primary":[285],"end":[286,302],"point":[287],"pathologic":[289],"complete":[290],"response":[291],"(pCR)":[292],"rate":[293,306],"axilla":[298],"(ypT0/Tis":[299],"ypN0).":[300],"Secondary":[301],"points":[303],"include":[304],"pCR":[305],"ypT0ypN0":[308],"ypT0/Tis,":[310],"residual":[311],"burden":[313],"index,":[314],"event":[315],"free":[316],"survival,":[317],"conserving":[319],"rate,":[321],"overall":[324],"survival.":[325],"Exploratory":[326],"correlative":[327],"studies":[328],"will":[329],"characterize":[330],"potential":[331],"immune":[332],"biomarkers":[333],"predictive":[334],"and/or":[337],"toxicity.":[338],"Clinical":[339],"information:":[341],"NCT03747120":[342],".":[343]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2023-06-05T00:00:00"}